SpringerLink
Log in

Mit bewährten und neuen Medikamenten

Herausforderungen der Tuberkulosetherapie

  • fortbildung
  • Published:
Pneumo News Aims and scope

Für die Behandlung der unkomplizierten, arzneimittelsensitiven Lungentuberkulose ist das seit 30 Jahren übliche sechsmonatige Standardschema nach wie vor aktuell. Mit Bedaquilin und Delamanid sind nun allerdings zwei neue Mittel zur Behandlung der Tuberkulose verfügbar. Im Nebenwirkungsprofil beider Medikamente ist das Potenzial für eine QT-Verlängerung zu beachten.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literaturverzeichnis

  1. Kalsdorf B, Olaru ID, Lange C, Heyckendorf J: Tuberkulose. Dtsch Med Wochenschr 2015; 140: 1508–12

    Article  Google Scholar 

  2. Warner DF, Mizrahi V: Shortening treatment for tuberculosis — back to basics. N Engl J Med 2014 Oct 23; 371(17): 1642–3

    Article  CAS  PubMed  Google Scholar 

  3. Lode HM, Stahlmann R: Aktuelle Therapie der Tuberkulose. Arzneimitteltherapie 2015; 33(3): 47–53

    Google Scholar 

  4. Gillespie SH, Crook AM, McHugh TD, Mendel CM, Meredith SK, Murray SR, Pappas F, Phillips PP, Nunn AJ; REMoxTB Consortium: Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis. N Engl J Med 2014 Oct 23; 371(17): 1577–87

    Article  PubMed Central  PubMed  Google Scholar 

  5. **dani A, Harrison TS, Nunn AJ, Phillips PP, Churchyard GJ, Charalambous S, Hatherill M, Geldenhuys H, McIlleron HM, Zvada SP, Mungofa S, Shah NA, Zizhou S, Magweta L, Shepherd J, Nyirenda S, van Dijk JH, Clouting HE, Coleman D, Bateson AL, McHugh TD, Butcher PD, Mitchison DA; RIFAQUIN Trial Team: High-dose rifapentine with moxifloxacin for pulmonary tuberculosis. N Engl J Med 2014 Oct 23; 371(17): 1599–608

    Article  PubMed Central  PubMed  Google Scholar 

  6. Merle CS, Fielding K, Sow OB, Gninafon M, Lo MB, Mthiyane T, Odhiambo J, Amukoye E, Bah B, Kassa F, N'Diaye A, Rustomjee R, de Jong BC, Horton J, Perronne C, Sismanidis C, Lapujade O, Olliaro PL, Lienhardt C; OFLOTUB/Gatifloxacin for Tuberculosis Project: A four-month gatifloxacin-containing regimen for treating tuberculosis. N Engl J Med 2014 Oct 23; 371(17): 1588–98. Erratum: N Engl J Med 2015 Apr 23; 372(17): 1677

    Article  PubMed  Google Scholar 

  7. Schaberg T, Otto-Knapp R, Bauer T: Kurze Übersicht über neue Medikamente zur Therapie der multiresistenten Tuberkulose. Pneumologie 2015; 69(5): 282–6

    Article  CAS  PubMed  Google Scholar 

  8. Millard J, Ugarte-Gil C, Moore DA: Multidrug resistant tuberculosis. BMJ 2015 Feb 26; 350: h882.

    Article  PubMed  Google Scholar 

  9. Brändli O: Tuberkulose aktuell. Schweiz Med Forum 2013; 13(25): 493–8

    Google Scholar 

  10. Donnerer J: Wechselwirkungen der hormonellen Kontrazeptiva. Gynäkologe 2011; 44: 31–36

    Article  CAS  Google Scholar 

  11. Schmiedel Y, Zimmerli S: Tuberkulose: Prävention, Latenz und Multiresistenz. Schweiz Med Forum 2015; 15(41): 918–24

    Google Scholar 

  12. Guglielmetti L, Le Dû D, Jachym M, Henry B, Martin D, Caumes E, Veziris N, M ä tivier N, Robert J; MDR-TB Management Group of the French National Reference Center for Mycobacteria and the Physicians of the French MDR-TB Cohort: Compassionate use of bedaquiline for the treatment of multidrug-resistant and extensively drug-resistant tuberculosis: interim analysis of a French cohort. Clin Infect Dis 2015 Jan 15; 60(2): 188–94

    Article  Google Scholar 

  13. Diacon AH, Pym A, Grobusch MP, de los Rios JM, Gotuzzo E, Vasilyeva I, Leimane V, Andries K, Bakare N, {pDe} Marez T, Haxaire-Theeuwes M, Lounis N, Meyvisch P, De Paepe E, van Heeswijk RP, Dannemann B; TMC207-C208 Study Group: Multidrug-resistant tuberculosis and culture conversion with bedaquiline. N Engl J Med 2014 Aug 21; 371(8): 723–32

    Article  PubMed  Google Scholar 

  14. Dawson R, Diacon AH, Everitt D, van Niekerk C, Donald PR, Burger DA, Schall R, Spigelman M, Conradie A, Eisenach K, Venter A, Ive P, Page-Shipp L, Variava E, Reither K, Ntinginya NE, Pym A, von Groote-Bidlingmaier F, Mendel CM: Efficiency and safety of the combination of moxi-floxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis. Lancet 2015 May 2; 385(9979): 1738–47

    Article  CAS  PubMed  Google Scholar 

  15. Gler MT, Skripconoka V, Sanchez-Garavito E, **ao H, Cabrera-Rivero JL, Vargas-Vasquez DE, Gao M, Awad M, Park SK, Shim TS, Suh GY, Danilovits M, Ogata H, Kurve A, Chang J, Suzuki K, Tupasi T, Koh WJ, Seaworth B, Geiter LJ, Wells CD: Delamanid for multidrug-resistant pulmonary tuberculosis. N Engl J Med 2012 Jun 7; 366 (23): 2151–60

    Article  CAS  PubMed  Google Scholar 

  16. Gupta R, Geiter LJ, Wells CD, Gao M, Cirule A, **ao H: Delamanid for extensively drug-resistant tuberculosis. N Engl J Med 2015 Jul 16; 373(3): 291–2

    Article  PubMed  Google Scholar 

  17. Olaru ID, von Groote-Bidlingmaier F, Heyckendorf J, Yew WW, Lange C, Chang KC: Novel drugs against tuberculosis: a clinician's perspective. Eur Respir J 2015 Apr; 45(4): 1119–31

    Article  CAS  PubMed  Google Scholar 

  18. Zumla A, Chakaya J, Centis R, D'Ambrosio L, Mwaba P, Bates M, Kapata N, Nyirenda T, Chanda D, Mfinanga S, Hoelscher M, Maeurer M, Migliori GB: Tuberculosis treatment and manage-ment — an update on treatment regimens, trials, new drugs, and adjunct therapies. Lancet Respir Med 2015 Mar; 3(3): 220–34

    Article  PubMed  Google Scholar 

  19. Dheda K, Barry CE 3rd, Maartens G: Tuberculosis. Lancet 2015 Sep 11. pii: S0140-6736(15)00151-8 [Epub ahead of print]

  20. Zumla AI, Gillespie SH, Hoelscher M, Philips PP, Cole ST, Abubakar I, McHugh TD, Schito M, Maeurer M, Nunn AJ: New antituberculosis drugs, regimens, and adjunct therapies: needs, advances, and future prospects. Lancet Infect Dis 2014; 14(4): 327–40

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Abteilung Klinische Pharmakologie, Universitätsklinikum Tübingen, Auf der Morgenstelle 8, 72076, Tübingen, Deutschland

    Klaus Mörike

Authors
  1. Klaus Mörike
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Klaus Mörike.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mörike, K. Herausforderungen der Tuberkulosetherapie. Pneumo News 7, 45–49 (2015). https://doi.org/10.1007/s15033-015-0277-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15033-015-0277-6

Search

Navigation